Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf, reykjavikurvegur 76-78, hafnarfjordur, island - ezetimibum, simvastatinum - tableta - 10 mg/20 mg - urbroj: svaka tableta sadrži 10 mg ezetimiba i 20 mg simvastatina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf, reykjavikurvegur 76-78, hafnarfjordur, island - ezetimibum, simvastatinum - tableta - 10 mg/40 mg - urbroj: svaka tableta sadrži 10 mg ezetimiba i 40 mg simvastatina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf, reykjavikurvegur 76-78, hafnarfjordur, island - ezetimibum, simvastatinum - tableta - 10 mg/80 mg - urbroj: svaka tableta sadrži 10 mg ezetimiba i 80 mg simvastatina

Europska Unija - hrvatski - EMA (European Medicines Agency)

actavis group ptc ehf    - pioglitazon hidroklorid - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone također pokazala da kombinacija inzulina u tip-2 dijabetesa kod odraslih pacijenata s nedostatnim nadzorom glukoze na inzulin, za koje je metformin nepraktično zbog kontraindikacija ili netolerancije. nakon početka terapije s пиоглитазоном, pacijenti moraju biti revidirani kroz 3-6 mjeseci za procjenu adekvatnosti odgovora na liječenje (e. smanjenje pokazatelja hba1c). kod bolesnika koji ne pokazuju adekvatan odgovor treba da se ukine pioglitazone. u svjetlu potencijalnih rizika za dugotrajno liječenje, propisane lijekove treba potvrditi u kasnijim rutinske inspekcije da dobro pioglitazone sprema.

Europska Unija - hrvatski - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. učinak иматиниба na ishod transplantacije koštane srži nije određena. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. iskustvo s иматинибом u bolesnika s mds/rafinerija u svezi s pdgfr генных permutacija-vrlo ograničen. nema kontroliranih istraživanja pokazuju kliničku korist ili povećanje preživljavanja za te bolesti.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf., reykjavikurvegur 76-78, hafnarfjordur, island - perindoprilum, indapamidum - filmom obložena tableta - 10 mg + 2,5 mg - urbroj: jedna filmom obložena tableta sadrži 10 mg perindoprilarginina što odgovara 6,79 mg perindoprila i 2,5 mg indapamid hemihidrata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf., reykjavikurvegur 76-78, hafnarfjordur, island - perindoprilum, indapamidum - filmom obložena tableta - 5 mg + 1,25 mg - urbroj: jedna filmom obložena tableta sadrži 5 mg perindoprilarginina što odgovara 3,395 mg perindoprila i 1,25 mg indapamid hemihidrata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf, reykjavikurvegur 76-78, hafnarfjordur, island - doksorubicinklorid - prašak za otopinu za injekciju ili infuziju - 10 mg - urbroj: 1 bočica s praškom za otopinu za injekciju ili infuziju sadržava 10 mg doksorubicinklorida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf, reykjavikurvegur 76-78, hafnarfjordur, island - doksorubicinklorid - prašak za otopinu za injekciju ili infuziju - 50 mg - urbroj: 1 bočica s praškom za otopinu za injekciju ili infuziju sadrži 50 mg doksorubicinklorida

Europska Unija - hrvatski - EMA (European Medicines Agency)

actavis group ptc ehf - dcsloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminici za sistemsku primjenu, - liječenje alergijskog rinitisa i urtikarije.